HR 7528 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To amend section 503B of the Federal Food, Drug, and Cosmetic Act to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market after a drug is in shortage.
Summary
This bill would amend federal regulations governing pharmaceutical outsourcing facilities (compounding pharmacies) to allow them a 180-day grace period to continue producing and distributing drugs after a drug shortage is declared to be over. Currently, outsourcing facilities are only authorized to compound and distribute certain drugs during declared shortages. The bill extends this authorization for up to 180 calendar days after a shortage ends, creating what the bill calls a "tail period" that gives facilities time to clear inventory and transition back to normal operations. This change applies to two sections of the Federal Food, Drug, and Cosmetic Act that govern outsourcing facility operations during drug shortages.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
Money behind the sponsor
Top reported contributors to Earl L. "Buddy" Carter’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- NULL $80,924
- INTERNATIONAL AUTO LOGISTICS $7,500
- SAVANNAH PILOTS ASSOC $6,600
- HENNESSY AUTOMOBILE COMPANIES $6,600
- SADOWSKI CO $6,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Earl L. "Buddy" Carter → · Outside spending →
Actions (2)
- Feb 12, 2026 Referred to the House Committee on Energy and Commerce. · house
- Feb 12, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
February 12, 2026
Mr. Carter of Georgia introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend section 503B of the Federal Food, Drug, and Cosmetic Act to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market after a drug is in shortage.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Growing America’s Pharmaceutical Supply Act” or the “GAP Supply Act”.
SEC. 2. PROVIDING FOR A TAIL PERIOD FOR OUTSOURCING FACILITIES TO COMPOUND AND DISTRIBUTE DRUGS IN SHORTAGE.
Section 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353b) is amended—
(1) in subsection (a)(2)(A)(ii), by striking “at the time” and inserting “within 180 calendar days”; and
(2) in subsection (d)(2)(A), by striking “at the time” and inserting “within 180 calendar days”. <all>
Comments